Host: |
HEK293 cells |
Reactivity: |
Human |
Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Short Description: |
Recombinant-Human ICAM-2/CD102-C-hFc&His protein was developed from hek293 cells and has a target region of C-hFc&His. For use in research applications. |
Formulation: |
Lyophilized from a 0.22 Mu m filtered solution of PBS, pH 7.4. Contact us for customized product form or formulation. |
Endotoxin: |
Please contact us for more information. |
Immunoreactivity: |
Measured by the ability of the immobilized protein to support the adhesion of THP-1 cells. When cells are added to ICAM-2 coated plates (12.5 Mu g/mL, 100 Mu L/well) , approximately >40% cells will adhere specifically after 60 minutes at 37 °C. |
Gene Symbol: |
ICAM2 |
Gene ID: |
3384 |
Uniprot ID: |
ICAM2_HUMAN |
Immunogen: |
Recombinant Human ICAM-2/CD102 Protein is produced by HEK293 expression system. The target protein is expressed with sequence (Lys25-Gln216) of human ICAM-2 (Accession #NP_000864.2) fused with an Fc, 6×His tag at the C-terminus. |
Function | ICAM proteins are ligands for the leukocyte adhesion protein LFA-1 (integrin alpha-L/beta-2). ICAM2 may play a role in lymphocyte recirculation by blocking LFA-1-dependent cell adhesion. It mediates adhesive interactions important for antigen-specific immune response, NK-cell mediated clearance, lymphocyte recirculation, and other cellular interactions important for immune response and surveillance. |
Protein Name | Intercellular Adhesion Molecule 2Icam-2Cd Antigen Cd102 |
Database Links | Reactome: R-HSA-198933Reactome: R-HSA-216083Reactome: R-HSA-5621575 |
Cellular Localisation | MembraneSingle-Pass Type I Membrane ProteinCell ProjectionMicrovillusCo-Localizes With RdxEzr And Msn In Microvilli |
Alternative Protein Names | Intercellular Adhesion Molecule 2 proteinIcam-2 proteinCd Antigen Cd102 proteinICAM2 protein |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance